California Public Employees Retirement System Increases Holdings in CVS Health Corporation $CVS

California Public Employees Retirement System grew its stake in CVS Health Corporation (NYSE:CVS) by 11.9% in the 1st quarter, Holdings Channel.com reports. The firm owned 2,536,408 shares of the pharmacy operator’s stock after purchasing an additional 269,363 shares during the period. California Public Employees Retirement System’s holdings in CVS Health were worth $182,165,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd grew its stake in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new stake in shares of CVS Health during the fourth quarter worth $26,000. Sankala Group LLC bought a new stake in shares of CVS Health during the fourth quarter worth $28,000. Global Trust Asset Management LLC boosted its stake in shares of CVS Health by 344.8% during the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health in the fourth quarter worth about $28,000. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Up 0.8%

Shares of CVS Health stock opened at $107.36 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a market cap of $136.99 billion, a P/E ratio of 47.30, a PEG ratio of 1.05 and a beta of 0.61. The firm’s 50 day moving average price is $98.97 and its 200-day moving average price is $85.13. CVS Health Corporation has a 52-week low of $58.50 and a 52-week high of $108.97.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter in the prior year, the company posted $2.25 earnings per share. CVS Health’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s payout ratio is 117.18%.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS opened its first pharmacy-focused location in Houston and plans to roll out nearly 20 similar sites, signaling an effort to expand access to in-person pharmacy care and strengthen its retail footprint. CVS Pharmacy® celebrates opening of first pharmacy-focused location in Houston
• Positive Sentiment: Management reiterated a constructive stance on GLP-1 drugs and pharmacy economics, with CEO comments highlighting that insurers may eventually cover weight-loss drugs more broadly once prices fall, reinforcing CVS’s role in cost management and pharmacy benefit services. CVS Health CEO David Joyner warns private insurers won’t cover GLP-1s for weight loss until drug prices drop
• Positive Sentiment: CVS also floated cost-saving solutions and a settlement in Georgia that could reduce prescription costs for some patients, which may improve public perception and support demand for its pharmacy services. New CVS settlement could lower prescription costs for some Georgians
• Neutral Sentiment: Coverage around CVS education benefits and talent development highlights workforce stability, but it is unlikely to have an immediate impact on the stock. At CVS, education benefits strengthen talent pipelines
• Neutral Sentiment: Broader analyst and media discussion of CVS’s dividend and GLP-1 strategy has helped reinforce the investment case, but this appears more supportive than a near-term catalyst. How Investors May Respond To CVS (CVS) Dividend Move And GLP?1 Strategy Across Its Health Platform

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. DA Davidson lifted their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Royal Bank Of Canada raised their target price on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Argus lifted their price target on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research note on Thursday, May 14th. HSBC reiterated a “hold” rating and issued a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Finally, Piper Sandler restated an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a report on Monday, June 1st. Twenty-one investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $105.38.

Insider Buying and Selling at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by company insiders.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.